Outcomes from a Novel Approach to Studying Consumer Genetic Testing for Germline Cancer and Cardiovascular Risk
American Journal of Medical Genetics Part A · 2025
DOI: 10.1002/ajmg.a.64169 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Medical Genetics Part A, 2025. Verfasst von Madison K Kilbride und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Philosophy, University of Utah, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Genetic Testing, Cardiovascular Diseases, Neoplasms. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHGRI NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Despite the growing availability of consumer genetic testing for serious disease risks, outcomes data remain limited for individuals undergoing testing for high‐ and moderate‐penetrance genes. To address this gap, we evaluated the feasibility of the Consumer Genetic Testing Outcomes Evaluation Paradigm (CGT‐OEP), a novel approach for studying cognitive, affective, and behavioral outcomes in individuals pursuing physician‐mediated genetic testing. We recruited participants to purchase Color Health's genetic test for cancer and cardiovascular disease risk. Participants completed Baseline (T0), Pre‐Disclosure (T1), and Two‐Week Post‐Disclosure (T2) surveys and shared results with the study team. Of 185 consented participants, 105 (56.8%) purchased tests, with 103 (98.1%) completing all requirements. Purchasers were predominantly white (89%), female (73%), and college‐educated (80%). Participants reported high satisfaction and minimal negative emotions, uncertainty, or decisional regret; most ( n = 67, 65%) planned to share results with providers. Although genetic knowledge increased and anxiety decreased post‐disclosure, many participants misinterpreted negative and VUS results as indicating lower‐than‐average risk for cancer ( n = 41, 42%) and cardiovascular disease ( n = 45, 46%). Our findings demonstrate that the CGT‐OEP is a feasible, effective approach for studying consumer genetic testing. While participants reported positive experiences, findings highlight concerns about result comprehension and potential false reassurance, particularly for negative/VUS results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Philosophy, University of Utah, Salt Lake City, Utah, USA.
- Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Division of Hematology-Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- College of Nursing, University of Utah, Salt Lake City, Utah, USA.
- Department of Health Behavior & Health Equity, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
- College of Engineering, University of Utah, Salt Lake City, Utah, USA.
ORCID-Profile: Madison K Kilbride, J Scott Roberts
Förderung
- NHGRI NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Kilbride, M. K., Chavez-Yenter, D., Wong, B., Roberts, J. S., Park, J., Iuliano, J., & Bradbury, A. R. (2025). Outcomes from a Novel Approach to Studying Consumer Genetic Testing for Germline Cancer and Cardiovascular Risk. American Journal of Medical Genetics Part A. https://doi.org/10.1002/ajmg.a.64169
Vancouver
Kilbride MK, Chavez-Yenter D, Wong B, Roberts JS, Park J, Iuliano J, et al. Outcomes from a Novel Approach to Studying Consumer Genetic Testing for Germline Cancer and Cardiovascular Risk. American Journal of Medical Genetics Part A. 2025. doi:10.1002/ajmg.a.64169
BibTeX
@article{Kilbride2025,
author = {Kilbride, Madison K and Chavez-Yenter, Daniel and Wong, Bob and Roberts, J Scott and Park, Jacqueline and Iuliano, Jason and Bradbury, Angela R},
title = {Outcomes from a Novel Approach to Studying Consumer Genetic Testing for Germline Cancer and Cardiovascular Risk},
journal = {American Journal of Medical Genetics Part A},
year = {2025},
doi = {10.1002/ajmg.a.64169}
}
EUVIMED